CRISPR Therapeutics AG Price Chart
CRISPR Therapeutics AG CRSPN.MX Financial and Trading Overview
CRISPR Therapeutics AG stock price | 1050 MXN |
Previous Close | 943 MXN |
Open | 0 MXN |
Bid | 765 MXN x N/A |
Ask | 850 MXN x N/A |
Day's Range | 0 - 0 MXN |
52 Week Range | 0 - 1400 MXN |
Volume | 0 MXN |
Avg. Volume | 26 MXN |
Market Cap | N/A |
Beta (5Y Monthly) | 1.614132 |
PE Ratio (TTM) | 12.052813 |
EPS (TTM) | 78.24 MXN |
Forward Dividend & Yield | N/A (N/A) |
Ex-Dividend Date | N/A |
1y Target Est | N/A |
CRSPN.MX Valuation Measures
Enterprise Value | 73.36B MXN |
Trailing P/E | 12.052813 |
Forward P/E | N/A |
PEG Ratio (5 yr expected) | N/A |
Price/Sales (ttm) | N/A |
Price/Book (mrq) | 41.21504 |
Enterprise Value/Revenue | 431.288 |
Enterprise Value/EBITDA | -162.032 |
Trading Information
CRISPR Therapeutics AG Stock Price History
Beta (5Y Monthly) | 1.614132 |
52-Week Change | N/A |
S&P500 52-Week Change | N/A |
52 Week High | 1400 MXN |
52 Week Low | 0 MXN |
50-Day Moving Average | 1038.18 MXN |
200-Day Moving Average | 1038.18 MXN |
CRSPN.MX Share Statistics
Avg. Volume (3 month) | 26 MXN |
Avg. Daily Volume (10-Days) | 22 MXN |
Shares Outstanding | N/A |
Float | 78.34M |
Short Ratio | N/A |
% Held by Insiders | 1.37% |
% Held by Institutions | 67.47% |
Shares Short | N/A |
Short % of Float | N/A |
Short % of Shares Outstanding | N/A |
Dividends & Splits
Trailing Annual Dividend Rate | 0 |
Trailing Annual Dividend Yield | 0% |
5 Year Average Dividend Yield | N/A |
Payout Ratio | N/A |
Last Split Factor |
Financial Highlights
Fiscal Year
Fiscal Year Ends | December 31, 2022 |
Most Recent Quarter (mrq) | June 30, 2023 |
Next Fiscal Year End | December 31, 2023 |
Profitability
Profit Margin | -244.51% |
Operating Margin (ttm) | -278.44% |
Gross Margin | -225.79% |
EBITDA Margin | -266.17% |
Management Effectiveness
Return on Assets (ttm) | -12.70% |
Return on Equity (ttm) | -21.29% |
Income Statement
Revenue (ttm) | 170.1M MXN |
Revenue Per Share (ttm) | 2.17 MXN |
Quarterly Revenue Growth (yoy) | 44203.80% |
Gross Profit (ttm) | -570697000 MXN |
EBITDA | -452763008 MXN |
Net Income Avi to Common (ttm) | -415928992 MXN |
Diluted EPS (ttm) | 78.239 |
Quarterly Earnings Growth (yoy) | N/A |
Balance Sheet
Total Cash (mrq) | 1.77B MXN |
Total Cash Per Share (mrq) | 22.27 MXN |
Total Debt (mrq) | 245.18M MXN |
Total Debt/Equity (mrq) | 13.5 MXN |
Current Ratio (mrq) | 13.999 |
Book Value Per Share (mrq) | 22.88 |
Cash Flow Statement
Operating Cash Flow (ttm) | -342992000 MXN |
Levered Free Cash Flow (ttm) | -248918368 MXN |
Profile of CRISPR Therapeutics AG
Country | Mexico |
State | N/A |
City | Zug |
Address | Baarerstrasse 14 |
ZIP | 6300 |
Phone | 41 41 561 32 77 |
Website | https://www.crisprtx.com |
Industry | |
Sector(s) | |
Full Time Employees | 458 |
CRISPR Therapeutics AG, a gene editing company, focuses on developing gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9) platform. Its CRISPR/Cas9 is a gene editing technology that allows for precise directed changes to genomic DNA. The company has a portfolio of therapeutic programs across a range of disease areas, including hemoglobinopathies, oncology, regenerative medicine, and rare diseases. The company's lead product candidate is CTX001, an ex vivo CRISPR gene-edited therapy for treating patients suffering from transfusion-dependent beta-thalassemia or severe sickle cell disease in which a patient's hematopoietic stem cells are engineered to produce high levels of fetal hemoglobin in red blood cells. It also develops CTX110, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting cluster of differentiation 19; CTX120, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting B-cell maturation antigen for the treatment of relapsed or refractory multiple myeloma; and CTX130, a donor-derived gene-edited allogeneic CAR-T investigational therapy targeting Cluster of Differentiation 70 to treat various solid tumors and hematologic malignancies. In addition, the company develops VCTX210, a gene-edited immune-evasive stem cell-derived product candidate for the treatment of treatment of type 1 diabetes; and VCTX211, an investigational, allogeneic, gene-edited, stem cell-derived product candidate for the treatment of T1D. It has strategic partnerships with Bayer Healthcare LLC, Vertex Pharmaceuticals Incorporated, ViaCyte, Inc., Nkarta, Inc., and Capsida Biotherapeutics. CRISPR Therapeutics AG was incorporated in 2013 and is headquartered in Zug, Switzerland.
Q&A For CRISPR Therapeutics AG Stock
What is a current CRSPN.MX stock price?
CRISPR Therapeutics AG CRSPN.MX stock price today per share is 1050 MXN.
How to purchase CRISPR Therapeutics AG stock?
You can buy CRSPN.MX shares on the Mexico exchange. Contact your financial advisor to select a broker.
What is the ticker symbol for CRISPR Therapeutics AG?
The stock symbol or ticker of CRISPR Therapeutics AG is CRSPN.MX.
How many shares does CRISPR Therapeutics AG have in circulation?
The max supply of CRISPR Therapeutics AG shares is 0.
What is CRISPR Therapeutics AG Price to Earnings Ratio (PE Ratio)?
CRISPR Therapeutics AG PE Ratio is 13.42041700 now.
What was CRISPR Therapeutics AG earnings per share over the trailing 12 months (TTM)?
CRISPR Therapeutics AG EPS is 78.24 MXN over the trailing 12 months.